Skip to main content

Table 1 Odds ratios for having the metabolic syndrome in patients receiving methotrexate monotherapy compared with those not on methotrexate

From: Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome - authors' response

 

NCEP 2004

NCEP 2001

 

OR (95% CI)

OR (95% CI)

 

n = 62

n = 62

Crude

0.415 (0.21-0.82),

0.368 (0.19-0.73),

 

P = 0.011

P = 0.004

Model a

0.421 (0.21-0.84),

0.373 (0.19-0.75),

 

P = 0.014

P = 0.006

Model b

0.468 (0.23-0.99),

0.408 (0.19-0.84),

 

P = 0.038

P = 0.015

  1. Crude: Unadjusted model. Model a: adjusted for age and gender. Model b: adjusted for age, gender, disease duration, erythrocyte sedimentation rate, and health assessment questionnaire score. CI, confidence interval; NCEP, National Cholesterol Education Program; OR, odds ratio.